Bio-Rad Laboratories, Inc. (NYSE:BIO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

According to Zacks, “Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company’s products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. “

Several other research firms have also issued reports on BIO. Jefferies Group LLC reissued a “buy” rating and issued a $275.00 price objective on shares of Bio-Rad Laboratories in a research report on Friday, July 14th. BidaskClub lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Deutsche Bank AG restated a “buy” rating and set a $255.00 target price on shares of Bio-Rad Laboratories in a report on Monday, September 18th. TheStreet cut shares of Bio-Rad Laboratories from a “b” rating to a “c+” rating in a research report on Thursday, August 3rd. Finally, Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They set an “outperform” rating and a $250.00 price target for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $240.80.

Shares of Bio-Rad Laboratories (NYSE:BIO) traded up 0.63% during mid-day trading on Wednesday, hitting $225.37. The stock had a trading volume of 68,570 shares. The company’s 50 day moving average price is $220.64 and its 200 day moving average price is $219.86. Bio-Rad Laboratories has a 12-month low of $154.89 and a 12-month high of $242.79. The stock has a market cap of $6.68 billion, a P/E ratio of 445.40 and a beta of 0.91.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/10/04/bio-rad-laboratories-inc-bio-upgraded-at-zacks-investment-research.html.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the completion of the sale, the executive vice president now owns 2,060 shares of the company’s stock, valued at $444,774.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.29% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board acquired a new position in shares of Bio-Rad Laboratories during the second quarter worth $113,000. Pacad Investment Ltd. purchased a new position in shares of Bio-Rad Laboratories in the second quarter valued at $113,000. Turner Investments LLC purchased a new position in shares of Bio-Rad Laboratories in the second quarter valued at $136,000. Capital Analysts LLC purchased a new position in shares of Bio-Rad Laboratories in the second quarter valued at $170,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Bio-Rad Laboratories by 12.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 815 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 90 shares during the period. Institutional investors own 62.84% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Get a free copy of the Zacks research report on Bio-Rad Laboratories (BIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.